Join
Live feed
·
PRReleasevia Quantisnow
Corcept Therapeutics Incorporated logo

Corcept Phase 2 Study of Dazucorilant Demonstrates Two-Year Overall Survival Benefit in Patients with Amyotrophic Lateral Sclerosis

ByQuantisnow·Wall Street's wire, on your screen.
CORT· Corcept Therapeutics Incorporated
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CORT (Corcept Therapeutics Incorporated) and more on Quantisnow.